EGFR and non-small cell lung carcinoma: A small Chinese retrospective cohort study21, involving 90 patients with advanced NSCLC and EGFR-activating mutations, found that patients who received EGFR-TKI plus metformin were linked to prolonged PFS and OS than those treated with EGFR-TKI monotherapy.